[{"orgOrder":0,"company":"Nora Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nora Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nora Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Nora Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Niopeg (pegfilgrastim) is an FDA-approved G-CSF agonist for treating febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

                          Brand Name : Niopeg

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 19, 2024

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank